Viridian Stock Soars 40% on Positive Drug Trial Results

Positive Trial Results Boost Viridian Shares

Viridian Therapeutics (NASDAQ:VRDN) shares surged 40% after the company reported positive topline results from its elegrobart Phase 3 REVEAL-2 clinical trial. The study focused on patients with chronic thyroid eye disease.

Overview of the REVEAL-2 Trial Success

The trial successfully met its primary endpoint, showing a highly statistically significant treatment effect. Proptosis responder rates at week 24 were 50% and 54% for different dosing regimens, compared to just 15% for the placebo group. The mean change from baseline in proptosis was -1.9 mm and -2.1 mm for the treatment groups, versus -0.5 mm for placebo.

Impact on Viridian and Market Outlook

This marks the second successful pivotal Phase 3 trial for elegrobart, a subcutaneously delivered antibody. This positive data reinforces the drug's profile and keeps the company on track to submit a Biologics License Application to the FDA in the first quarter of 2027. Viridian reported cash and marketable securities of $762.2 million as of March 31, 2026, positioning it well for future development.

Future Projections

With consistent safety data and strong efficacy results from two major trials, market confidence in elegrobart has significantly increased. The company plans to launch the treatment as an at-home autoinjector, which could enhance its market adoption upon approval.

FAQ

Q: Why did Viridian Therapeutics' stock price increase sharply?
A: The stock surged 40% following the announcement of highly positive and statistically significant results from its Phase 3 REVEAL-2 clinical trial for the thyroid eye disease drug, elegrobart.

Q: What is the next major step for Viridian's drug elegrobart?
A: Viridian Therapeutics plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027.

Source: Investing.com